Reduces Nrf2 expression in non-small-cell lung cancer cells, leading to GSH depletion [160]Sensitizes cells to oxaliplatin, bleomycin, doxorubicin [160,161]. Re-sensitizes oxaliplatin-resistant colorectal cancer cells [68]Inhibits Nrf2 in xenografts [162]. The gene discussed is NFE2L2; the disease is colorectal cancer.